CR Bard's third quarter improved by acquisition
This article was originally published in Clinica
CR Bard, which completed the takeover of MedChem Products on September 28th, has reported combined third-quarter results. Net income is depressed by a one-time after-tax charge of $9.9 million for merger costs. In the first nine months some 34% of sales were contributed by international revenues.